Sign up
Pharma Capital

Drug developer Faron Pharmaceuticals to appoint two industry heavyweights to the board

Dr Gregory Brown and John Poulos bring with them a breadth and depth of industry experience
chairs around a boardroom table
There will be two new faces around the boardroom table

Drug developer Faron Pharmaceuticals Ltd (LON:FARN) has unveiled plans to appoint two new independent directors.

They are Dr Gregory Brown and John Poulos, who bring with them a breadth and depth of industry experience.

Brown has spent 35 years working in healthcare and investment and he founded HealthCare Royalty Partners, a private asset management firm investing in biopharmaceutical and medical products. He is also a director of NASDAQ-listed Caladrius Biosciences and Nuron Biotech.

Poulos, meanwhile, is a 38-year sector veteran and has held senior roles at AbbVie and Abbott and was most recently head of licensing and acquisitions for the former.

During his career, he was instrumental in negotiating numerous acquisitions, Faron said, including the purchases of Knoll/BASF Pharma in 2001 for US$6.9bn and Solvay in 2010 for US$6.2bn.

Chairman Dr Frank Armstrong said: “They will both bring a wealth of global experience in the life sciences and investment community to strengthen our board, particularly from a US and commercial angle, as we continue to progress through a pivotal year.”

The appointments of the two new non-execs will be formally ratified at the company’s annual meeting next month.

Separately, Faron said Dr Juho Jalkanen is stepping down from the board as a non-executive director to take on the role of vice president of business development with the company.

Ian_55ae0ddd437b7.jpg
Why Invest In Faron Pharmaceuticals Oy? Read More Here

Register here to be notified of future FARN Company articles
View full FARN profile

Faron Pharmaceuticals Oy Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.